Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Schilling

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
The Prostate|January 15, 2015
Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancerTilman Todenhöfer, Jörg Hennenlotter, Frank Faber, et al.
World Journal of Urology|October 16, 2012
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsyStephan Kruck, Aristoteles G Anastasiadis, Thomas R W Herrmann, et al.
Plos One|December 20, 2012
Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancerMartin Heni, Jörg Hennenlotter, Marcus Scharpf, et al.
World Journal of Urology|October 5, 2011
XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrenceStefan Aufderklamm, Jörg Hennenlotter, Tilman Todenhoefer, et al.
Cancer Research and Treatment|December 9, 2014
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot StudyIgor Tsaur, Anika Noack, Jasmina Makarevic, et al.
Histopathology|June 29, 2011
Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancerMartin Braun, Veit J Scheble, Roopika Menon, et al.
The Prostate|June 21, 2012
Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastasesTilman Todenhöfer, Jörg Hennenlotter, Benjamin Joachim Schmiedel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 18, 2010
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumorVeit J Scheble, Martin Braun, Rameen Beroukhim, et al.
Cancers|November 11, 2022
Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional IMPROVE StudyIngmar Wolff, Martin Burchardt, Christian Gilfrich, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 4, 2015
Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter studyAlexander Karl, Alexander Buchner, Christiane Tympner, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The Prostate|January 15, 2015
Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancerTilman Todenhöfer, Jörg Hennenlotter, Frank Faber, et al.
World Journal of Urology|October 16, 2012
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsyStephan Kruck, Aristoteles G Anastasiadis, Thomas R W Herrmann, et al.
Plos One|December 20, 2012
Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancerMartin Heni, Jörg Hennenlotter, Marcus Scharpf, et al.
World Journal of Urology|October 5, 2011
XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrenceStefan Aufderklamm, Jörg Hennenlotter, Tilman Todenhoefer, et al.
Cancer Research and Treatment|December 9, 2014
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot StudyIgor Tsaur, Anika Noack, Jasmina Makarevic, et al.
Histopathology|June 29, 2011
Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancerMartin Braun, Veit J Scheble, Roopika Menon, et al.
The Prostate|June 21, 2012
Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastasesTilman Todenhöfer, Jörg Hennenlotter, Benjamin Joachim Schmiedel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 18, 2010
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumorVeit J Scheble, Martin Braun, Rameen Beroukhim, et al.
Cancers|November 11, 2022
Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional IMPROVE StudyIngmar Wolff, Martin Burchardt, Christian Gilfrich, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 4, 2015
Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter studyAlexander Karl, Alexander Buchner, Christiane Tympner, et al.
Pageof 9